Sanofi-Aventis Sues Apotex Over ANDA For Eloxatin
In a complaint filed Wednesday in the U.S. District Court for the District of New Jersey, the French drugmaker claims Apotex's abbreviated new drug application with the U.S. Food and Drug Administration to make generic Eloxatin constitutes infringement of U.S. Patent Number 5,338,874.
The '874 patent is listed in the FDA's Orange Book for Eloxatin. Sanofi-Aventis licenses the patent...
To view the full article, register now.